E13 Non-Hodgkin lymphoma: how to proceed

Multiple mechanisms can disrupt oncogenic pathways in multiple myeloma

“…Notably, mutations in the PAX5 CRE identified resulted in a 4.6-fold reduced expression, consistent with PAX5 being a tumour suppressor as in other B-cell malignancies [ 4 - 6 ]. In contrast, disruption of ST6GAL1 CRE by SNVs led to a 1.4-fold upregulation, consistent with ST6GAL1 is overexpressed in various cancers [ 7 ] and aberrant glycosylation in MM [ 8 ].…”